• Clinical Evidence

Evaluating the Effect of EndoTool Utilization for Glycemic Control in Critically Ill Patients at UPMC

Image
Setting: UPMC Central PA

Objective

To assess the impact of EndoTool IV, insulin dosing software, on clinical outcomes in two critical care units.

Setting

Comparison of patient outcomes pre-and post EndoTool IV implementation in two critical care units at UPMC Central PA over three months.

Results

  • Insulin Infusion Duration: After implementing ETIV, there was a substantial reduction in the average time patients spent on insulin infusion, decreasing from 58.16 hours to 41.4 hours.
  • Blood Glucose Management: The average time to reach the target blood glucose level of 140 mg/dl was significantly reduced from 18 hours and 15 minutes to just 4.7 hours. Furthermore, the rate of hypoglycemic events (blood glucose < 70 mg/dl) decreased from 2.11% to 0.530%.
  • Hospital Stay Metrics:
    • ICU Length of Stay (LOS): The average ICU LOS decreased from 5.3 days to 4.76 days.
    • Hospital LOS: There was a reduction in the average hospital stay from 11 days to 8.6 days.
  • Cost Implications: The average ICU charges per patient saw a decrease, going from $42,032 to $32,162.
  • Blood Glucose Monitoring Frequency: The average number of blood glucose checks while on an insulin drip reduced from 67 to 31.2 checks.
  • Severe Hypoglycemia: Complete elimination of severe hypoglycemia (blood glucose < 40 mg/dl) post-ETIV implementation, compared to 0.14% pre-implementation.

Conclusions

These results demonstrate the effectiveness of EndoTool IV in improving glycemic control, reducing the duration of insulin infusion, and minimizing the incidence of hypoglycemic events in critically ill patients. Additionally, the reduction in ICU and overall hospital stay, along with a decrease in ICU charges, suggests potential cost-effectiveness of this intervention.

Objective

To assess the impact of EndoTool IV, insulin dosing software, on clinical outcomes in two critical care units.

Setting

Comparison of patient outcomes pre-and post EndoTool IV implementation in two critical care units at UPMC Central PA over three months.

Results

  • Insulin Infusion Duration: After implementing ETIV, there was a substantial reduction in the average time patients spent on insulin infusion, decreasing from 58.16 hours to 41.4 hours.
  • Blood Glucose Management: The average time to reach the target blood glucose level of 140 mg/dl was significantly reduced from 18 hours and 15 minutes to just 4.7 hours. Furthermore, the rate of hypoglycemic events (blood glucose < 70 mg/dl) decreased from 2.11% to 0.530%.
  • Hospital Stay Metrics:
    • ICU Length of Stay (LOS): The average ICU LOS decreased from 5.3 days to 4.76 days.
    • Hospital LOS: There was a reduction in the average hospital stay from 11 days to 8.6 days.
  • Cost Implications: The average ICU charges per patient saw a decrease, going from $42,032 to $32,162.
  • Blood Glucose Monitoring Frequency: The average number of blood glucose checks while on an insulin drip reduced from 67 to 31.2 checks.
  • Severe Hypoglycemia: Complete elimination of severe hypoglycemia (blood glucose < 40 mg/dl) post-ETIV implementation, compared to 0.14% pre-implementation.

Conclusions

These results demonstrate the effectiveness of EndoTool IV in improving glycemic control, reducing the duration of insulin infusion, and minimizing the incidence of hypoglycemic events in critically ill patients. Additionally, the reduction in ICU and overall hospital stay, along with a decrease in ICU charges, suggests potential cost-effectiveness of this intervention.

References

Authors

Kinza Salim, DO; Josephine Gomes, DO; Evelyn Calderon Martinez, MD; Danya Abedeen, DO; Zachary Scheid, DO; Rabiah Riaz, MD; Lauren Ortiz; Anderson Schrader; Amy Helmuth, DNP, FACHE; Soni Srivastav, MD; Paul Chidester, MD, FACP; Anas Atrash, MD, FACP

Source

23rd Annual Diabetes Technology Meeting

Year

2023

Quick navigation
Objective
Setting
Results
Conclusions
References

Objective

To assess the impact of EndoTool IV, insulin dosing software, on clinical outcomes in two critical care units.

Setting

Comparison of patient outcomes pre-and post EndoTool IV implementation in two critical care units at UPMC Central PA over three months.

Results

  • Insulin Infusion Duration: After implementing ETIV, there was a substantial reduction in the average time patients spent on insulin infusion, decreasing from 58.16 hours to 41.4 hours.
  • Blood Glucose Management: The average time to reach the target blood glucose level of 140 mg/dl was significantly reduced from 18 hours and 15 minutes to just 4.7 hours. Furthermore, the rate of hypoglycemic events (blood glucose < 70 mg/dl) decreased from 2.11% to 0.530%.
  • Hospital Stay Metrics:
    • ICU Length of Stay (LOS): The average ICU LOS decreased from 5.3 days to 4.76 days.
    • Hospital LOS: There was a reduction in the average hospital stay from 11 days to 8.6 days.
  • Cost Implications: The average ICU charges per patient saw a decrease, going from $42,032 to $32,162.
  • Blood Glucose Monitoring Frequency: The average number of blood glucose checks while on an insulin drip reduced from 67 to 31.2 checks.
  • Severe Hypoglycemia: Complete elimination of severe hypoglycemia (blood glucose < 40 mg/dl) post-ETIV implementation, compared to 0.14% pre-implementation.

Conclusions

These results demonstrate the effectiveness of EndoTool IV in improving glycemic control, reducing the duration of insulin infusion, and minimizing the incidence of hypoglycemic events in critically ill patients. Additionally, the reduction in ICU and overall hospital stay, along with a decrease in ICU charges, suggests potential cost-effectiveness of this intervention.

References

Authors

Kinza Salim, DO; Josephine Gomes, DO; Evelyn Calderon Martinez, MD; Danya Abedeen, DO; Zachary Scheid, DO; Rabiah Riaz, MD; Lauren Ortiz; Anderson Schrader; Amy Helmuth, DNP, FACHE; Soni Srivastav, MD; Paul Chidester, MD, FACP; Anas Atrash, MD, FACP

Source

23rd Annual Diabetes Technology Meeting

Year

2023

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Image
  • Clinical Evidence

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

20 minute read

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

The objective of this study was to evaluate the impact of different blood glucose (BG) target ranges for IV insulin infusions on inpatient glucose metrics, specifically focusing on hypo and hyperglycemic events, duration of IV insulin therapy, and length of stay (LOS) in the hospital.
Image
  • Clinical Evidence

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.